Skip to main content
SpringerLink
Log in

Gallbladder Cancer

  • Chapter
  • First Online:
Evaluation and Management of Liver Masses

  • 313 Accesses

Abstract

Gallbladder cancer (GBC) is the most common malignant tumor of the biliary tract representing 80–95% of biliary tract cancers worldwide. The disease has a striking variability in the incidence, being most common in some countries such as Chile, North India, and Japan, and less common in western countries such as the United States. Most cases are diagnosed at late stages due to vague symptoms, and only 10–30% of patients are candidates for curative resection. Given the rarity of the disease in many parts of the world, contemporary clinical data are limited to a few clinical trials. Moreover, patients with GBC are often combined with other biliary tract cancers in clinical trials. Nevertheless, the treatment of gallbladder cancer has evolved over the last decade with an increased emphasis on the use of therapies such as intensity-modulated radiotherapy (IMRT), molecular targeted therapy, and combination chemotherapy. In addition, randomized controlled trials are evaluating the roles of chemotherapy and molecular-targeted therapy in the management of the disease. In this chapter, we detail the contemporary clinical management of gallbladder cancer with a special focus on the latest developments in the field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–602. https://doi.org/10.1002/ijc.21683.

    Article  CAS  PubMed  Google Scholar 

  2. Al-alem F, Mattar RE, Madkhali A, Alsharabi A, Alsaif F, Hassanain M. Incidental gallbladder cancer. In: Abdeldayem HM, editor. Updates in gallbladder diseases. Ch. 06. Rijeka: InTech; 2017.

    Google Scholar 

  3. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109. https://doi.org/10.2147/CLEP.S37357.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA. 1983;250(17):2323–6.

    Article  CAS  PubMed  Google Scholar 

  5. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167–76.

    Article  PubMed  Google Scholar 

  6. Nagorney DM, McPherson GA. Carcinoma of the gallbladder and extrahepatic bile ducts. Semin Oncol. 1988;15(2):106–15.

    CAS  PubMed  Google Scholar 

  7. Shukla VK, Tiwari SC, Roy SK. Biliary bile acids in cholelithiasis and carcinoma of the gall bladder. Eur J Cancer Prev. 1993;2(2):155–60.

    Article  CAS  PubMed  Google Scholar 

  8. Niu X-J, Wang Z-R, Wu S-L, Geng Z-M, Zhang Y-F, Qing X-L. Relationship between inducible nitric oxide synthase expression and angiogenesis in primary gallbladder carcinoma tissue. World J Gastroenterol. 2004;10(5):725–8. https://doi.org/10.3748/wjg.v10.i5.725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shukla VK, Tiwari SC, Roy SK. Biliary bile acids in cholelithiasis and carcinoma of the gall bladder. European J Cancer Prevention: Official Journal of the European Cancer Prevention Organisation (ECP). 1993;2(2):155–60.

    Article  CAS  Google Scholar 

  10. Kumar S, Kumar S, Kumar S. Infection as a risk factor for gallbladder cancer. J Surg Oncol. 2006;93(8):633–9. https://doi.org/10.1002/jso.20530.

    Article  PubMed  Google Scholar 

  11. Nervi F, Duarte I, Gomez G, Rodriguez G, Del Pino G, Ferrerio O, et al. Frequency of gallbladder cancer in Chile, a high-risk area. Int J Cancer. 1988;41(5):657–60.

    Article  CAS  PubMed  Google Scholar 

  12. Shukla VK, Khandelwal C, Roy SK, Vaidya MP. Primary carcinoma of the gall bladder: a review of a 16-year period at the university hospital. J Surg Oncol. 1985;28(1):32–5.

    Article  CAS  PubMed  Google Scholar 

  13. Caygill CP, Hill MJ, Braddick M, Sharp JC. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet (London, England). 1994;343(8889):83–4.

    Article  CAS  Google Scholar 

  14. Strom BL, Soloway RD, Rios-Dalenz JL, Rodriguez-Martinez HA, West SL, Kinman JL, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer. 1995;76(10):1747–56.

    Article  CAS  PubMed  Google Scholar 

  15. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol. 2007;31(6):907–13. https://doi.org/10.1097/01.pas.0000213435.99492.8a.

    Article  PubMed  Google Scholar 

  16. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109. https://doi.org/10.2147/clep.s37357.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (Baltimore, Md). 2011;54(5):1842–52. https://doi.org/10.1002/hep.24570.

    Article  Google Scholar 

  18. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery. 2001;129(6):699–703. https://doi.org/10.1067/msy.2001.113888.

    Article  CAS  PubMed  Google Scholar 

  19. Khan ZS, Livingston EH, Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature. Arch Surg (Chicago, Ill: 1960). 2011;146(10):1143–7. https://doi.org/10.1001/archsurg.2011.257.

    Article  Google Scholar 

  20. Wiles R, Thoeni RF, Barbu ST, Vashist YK, Rafaelsen SR, Dewhurst C, et al. Management and follow-up of gallbladder polyps: Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). Eur Radiol. 2017;27(9):3856–66. https://doi.org/10.1007/s00330-017-4742-y.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Sebastian S, Araujo C, Neitlich JD, Berland LL. Managing incidental findings on abdominal and pelvic CT and MRI, part 4: white paper of the ACR incidental findings committee II on gallbladder and biliary findings. J Am Coll Radiol: JACR. 2013;10(12):953–6. https://doi.org/10.1016/j.jacr.2013.05.022.

    Article  PubMed  Google Scholar 

  22. Mori Y, Sato N, Matayoshi N, Tamura T, Minagawa N, Shibao K, et al. Rare combination of familial adenomatous polyposis and gallbladder polyps. World J Gastroenterol: WJG. 2014;20(46):17661–5. https://doi.org/10.3748/wjg.v20.i46.17661.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shaffer EA. Gallbladder Cancer: the basics. Gastroenterol Hepatol. 2008;4(10):737–41.

    Google Scholar 

  24. Buscemi S, Orlando E, Damiano G, Portelli F, Palumbo VD, Valentino A, et al. "Pure" large cell neuroendocrine carcinoma of the gallbladder. Report of a case and review of the literature. Inter J Surg (London, England). 2016;28(Suppl 1):S128–32. https://doi.org/10.1016/j.ijsu.2015.12.045.

    Article  Google Scholar 

  25. Dursun N, Escalona OT, Roa JC, Basturk O, Bagci P, Cakir A, et al. Mucinous carcinomas of the gallbladder: Clinicopathologic analysis of 15 cases identified in 606 carcinomas. Arch Pathol Lab Med. 2012;136(11):1347–58. https://doi.org/10.5858/arpa.2011-0447-OA.

    Article  PubMed  Google Scholar 

  26. Bal MM, Ramadwar M, Deodhar K, Shrikhande S. Pathology of gallbladder carcinoma: current understanding and new perspectives. Pathol Oncol Res. 2015;21(3):509–25. https://doi.org/10.1007/s12253-014-9886-3.

    Article  CAS  PubMed  Google Scholar 

  27. Saetta AA. K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer. J Surg Oncol. 2006;93(8):644–9. https://doi.org/10.1002/jso.20532.

    Article  CAS  PubMed  Google Scholar 

  28. Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. BMC Cancer. 2006;6:126. https://doi.org/10.1186/1471-2407-6-126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhou YM, Li YM, Cao N, Feng Y, Zeng F. [significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. Ai zheng = Aizheng =. Chin J Cancer. 2003;22(3):262–5.

    CAS  Google Scholar 

  30. Dwivedi AND, Jain S, Dixit R. Gall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases: WJCC. 2015;3(3):231–44. https://doi.org/10.12998/wjcc.v3.i3.231.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Vega EA, Vinuela E, Yamashita S, Sanhueza M, Cavada G, Diaz C, et al. Extended lymphadenectomy is required for incidental gallbladder Cancer independent of cystic duct lymph node status. J Gastrointest Surg. 2018;22(1):43–51. https://doi.org/10.1007/s11605-017-3507-x.

    Article  PubMed  Google Scholar 

  32. Redaelli CA, Buchler MW, Schilling MK, Krahenbuhl L, Ruchti C, Blumgart LH, et al. High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery. 1997;121(1):58–63.

    Article  CAS  PubMed  Google Scholar 

  33. Prasad TL, Kumar A, Sikora SS, Saxena R, Kapoor VK. Mirizzi syndrome and gallbladder cancer. J Hepato-Biliary-Pancreat Surg. 2006;13(4):323–6. https://doi.org/10.1007/s00534-005-1072-2.

    Article  Google Scholar 

  34. Regimbeau JM, Fuks D, Bachellier P, Le Treut YP, Pruvot FR, Navarro F, et al. Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group. European Journal Of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2011;37(6):505–12. https://doi.org/10.1016/j.ejso.2011.03.135.

    Article  CAS  Google Scholar 

  35. Rooholamini SA, Tehrani NS, Razavi MK, Au AH, Hansen GC, Ostrzega N, et al. Imaging of gallbladder carcinoma. Radiographics: A Review Publication of the Radiological Society of North America, Inc. 1994;14(2):291–306. https://doi.org/10.1148/radiographics.14.2.8190955.

    Article  CAS  Google Scholar 

  36. Kim JH, Kim TK, Eun HW, Kim BS, Lee MG, Kim PN, et al. Preoperative evaluation of gallbladder carcinoma: efficacy of combined use of MR imaging, MR cholangiography, and contrast-enhanced dual-phase three-dimensional MR angiography. J Magn Reson Imaging: JMRI. 2002;16(6):676–84. https://doi.org/10.1002/jmri.10212.

    Article  PubMed  Google Scholar 

  37. Kokudo N, Makuuchi M, Natori T, Sakamoto Y, Yamamoto J, Seki M, et al. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg (Chicago, Ill: 1960). 2003;138(7):741–50.; ; discussion 50. https://doi.org/10.1001/archsurg.138.7.741.

    Article  Google Scholar 

  38. Butte JM, Gonen M, Allen PJ, D'Angelica MI, Kingham TP, Fong Y, et al. The role of laparoscopic staging in patients with incidental gallbladder cancer. HPB (Oxford). 2011;13(7):463–72. https://doi.org/10.1111/j.1477-2574.2011.00325.x.

    Article  Google Scholar 

  39. Agarwal AK, Kalayarasan R, Javed A, Gupta N, Nag HH. The role of staging laparoscopy in primary gall bladder cancer--an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. Ann Surg. 2013;258(2):318–23. https://doi.org/10.1097/SLA.0b013e318271497e.

    Article  PubMed  Google Scholar 

  40. Chun YS, Pawlik TM, Vauthey J-N. 8th edition of the AJCC Cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2017; https://doi.org/10.1245/s10434-017-6025-x.

  41. Reid KM. Ramos-De la Medina a, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11(5):671–81. https://doi.org/10.1007/s11605-006-0075-x.

    Article  PubMed  Google Scholar 

  42. Lee JM, Kim BW, Kim WH, Wang HJ, Kim MW. Clinical implication of bile spillage in patients undergoing laparoscopic cholecystectomy for gallbladder cancer. Am Surg. 2011;77(6):697–701.

    PubMed  Google Scholar 

  43. Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, et al. Gallbladder Cancer: expert consensus statement. HPB (Oxford). 2015;17(8):681–90. https://doi.org/10.1111/hpb.12444.

    Article  PubMed Central  Google Scholar 

  44. Shirai Y, Wakai T, Sakata J, Hatakeyama K. Regional lymphadenectomy for gallbladder cancer: rational extent, technical details, and patient outcomes. World J Gastroenterol. 2012;18(22):2775–83. https://doi.org/10.3748/wjg.v18.i22.2775.

    Article  PubMed  PubMed Central  Google Scholar 

  45. D'Angelica M, Dalal KM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16(4):806–16. https://doi.org/10.1245/s10434-008-0189-3.

    Article  PubMed  Google Scholar 

  46. Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, et al. Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci. 2015;22(4):249–73. https://doi.org/10.1002/jhbp.233.

    Article  PubMed  Google Scholar 

  47. Pawlik TM, Gleisner AL, Vigano L, Kooby DA, Bauer TW, Frilling A, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11(11):1478–86.; ; discussion 86-7. https://doi.org/10.1007/s11605-007-0309-6.

    Article  PubMed  Google Scholar 

  48. Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000;232(4):557–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ouchi K, Mikuni J, Kakugawa Y. Laparoscopic cholecystectomy for gallbladder carcinoma: results of a Japanese survey of 498 patients. J Hepato-Biliary-Pancreat Surg. 2002;9(2):256–60. https://doi.org/10.1007/s005340200028.

    Article  Google Scholar 

  50. Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg. 2008;247(1):104–8. https://doi.org/10.1097/SLA.0b013e318154bf5d.

    Article  PubMed  Google Scholar 

  51. Chijiiwa K, Noshiro H, Nakano K, Okido M, Sugitani A, Yamaguchi K, et al. Role of surgery for gallbladder carcinoma with special reference to lymph node metastasis and stage using western and Japanese classification systems. World J Surg. 2000;24(10):1271–6; discussion 7.

    Article  CAS  PubMed  Google Scholar 

  52. Yamamoto M, Onoyama H, Ajiki T, Yamada I, Fujita T, Saitoh Y. Surgical results of operations for carcinoma of the gallbladder. Hepato-Gastroenterology. 1999;46(27):1552–6.

    CAS  PubMed  Google Scholar 

  53. Itoh H, Nishijima K, Kurosaka Y, Takegawa S, Kiriyama M, Dohba S, et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci. 2005;50(12):2231–42. https://doi.org/10.1007/s10620-005-3040-8.

    Article  PubMed  Google Scholar 

  54. Todoroki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y, et al. Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepato-Gastroenterology. 1999;46(27):1585–91.

    CAS  PubMed  Google Scholar 

  55. Kim Y, Amini N, Wilson A, Margonis GA, Ethun CG, Poultsides G, et al. Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder Cancer: a multi-institutional analysis. Ann Surg Oncol. 2016;23(9):2998–3008. https://doi.org/10.1245/s10434-016-5262-8.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Mitin T, Enestvedt CK, Jemal A, Sineshaw HM. Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival. J Natl Cancer Inst. 2017;109(7) https://doi.org/10.1093/jnci/djw324.

  57. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant Capecitabine and gemcitabine followed by radiotherapy and concurrent Capecitabine in extrahepatic Cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol: Official Journal of the American Society of Clinical Oncology. 2015;33(24):2617–22. https://doi.org/10.1200/jco.2014.60.2219.

    Article  CAS  Google Scholar 

  58. Sun XN, Wang Q, Gu BX, Zhu YH, Hu JB, Shi GZ, et al. Adjuvant radiotherapy for gallbladder cancer: a dosimetric comparison of conformal radiotherapy and intensity-modulated radiotherapy. World J Gastroenterol. 2011;17(3):397–402. https://doi.org/10.3748/wjg.v17.i3.397.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Fuller CD, Thomas CR Jr, Wong A, Cavanaugh SX, Salter BJ, Herman TS, et al. Image-guided intensity-modulated radiation therapy for gallbladder carcinoma. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2006;81(1):65–72. https://doi.org/10.1016/j.radonc.2006.08.013.

    Article  Google Scholar 

  60. Engineer R, Goel M, Chopra S, Patil P, Purandare N, Rangarajan V, et al. Neoadjuvant Chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm. Ann Surg Oncol. 2016;23(9):3009–15. https://doi.org/10.1245/s10434-016-5197-0.

    Article  PubMed  Google Scholar 

  61. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96(6):896–902. https://doi.org/10.1038/sj.bjc.6603648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for Unresectable biliary tract Cancer. Jpn J Clin Oncol. 2007;37(11):843–51. https://doi.org/10.1093/jjco/hym116.

    Article  PubMed  Google Scholar 

  63. Gallardo J, Rubio B, Villanueva L, Barajas O. Gallbladder Cancer, a different disease that needs individual trials. J Clin Oncol. 2005;23(30):7753–4. https://doi.org/10.1200/JCO.2005.02.7524.

    Article  PubMed  Google Scholar 

  64. Kelley RK, Bardeesy N. Biliary tract cancers: finding better ways to lump and Split. J Clin Oncol. 2015;33(24):2588–90. https://doi.org/10.1200/JCO.2015.61.6953.

    Article  CAS  PubMed  Google Scholar 

  65. Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. Journal of Clinical Oncology. 2017;35(15_suppl):4006. https://doi.org/10.1200/JCO.2017.35.15_suppl.4006.

    Article  Google Scholar 

  66. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract Cancer. N Engl J Med. 2010;362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721.

    Article  CAS  PubMed  Google Scholar 

  67. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg. 2009;250(6):950–6.

    Article  PubMed  Google Scholar 

  68. Sirohi B, Singh A, Jagannath P, Shrikhande SV. Chemotherapy and targeted therapy for gall bladder Cancer. Indian J Surg Oncol. 2014;5(2):134–41. https://doi.org/10.1007/s13193-014-0317-4.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Oswalt CE, Cruz AB Jr. Effectiveness of chemotherapy in addition to surgery in treating carcinoma of the gallbladder. Rev Surg. 1977;34(6):436–8.

    CAS  PubMed  Google Scholar 

  70. Raj D, Singh S, Gupta N, Rathi S. Neoadjuvant chemotherapy for gall bladder cancer: Does it increase resectability? J Clin Oncol. 2016;34(4_suppl):406. https://doi.org/10.1200/jco.2016.34.4_suppl.406.

    Article  Google Scholar 

  71. Sirohi B, Mitra A, Jagannath P, Singh A, Ramadvar M, Kulkarni S, et al. Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer. Future Oncol (London, England). 2015;11(10):1501–9. https://doi.org/10.2217/fon.14.308.

    Article  CAS  Google Scholar 

  72. Engineer R, Wadasadawala T, Mehta S, Mahantshetty U, Purandare N, Rangarajan V, et al. Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism? J Gastrointest Cancer. 2011;42(4):222–7. https://doi.org/10.1007/s12029-010-9179-3.

    Article  PubMed  Google Scholar 

  73. de Aretxabala X, Roa I, Burgos L, Cartes R, Silva J, Yañez E, et al. Preoperative chemoradiotherapy in the treatment of gallbladder cancer. Am Surg. 1999;65(3):241–6.

    PubMed  Google Scholar 

  74. Saluja SS, Gulati M, Garg PK, Pal H, Pal S, Sahni P, et al. Endoscopic or Percutaneous Biliary Drainage for Gallbladder Cancer: A Randomized Trial and Quality of Life Assessment. Clin Gastroenterol Hepatol. 2008;6(8):944–50.e3. https://doi.org/10.1016/j.cgh.2008.03.028.

    Article  PubMed  Google Scholar 

  75. Pinol V, Castells A, Bordas JM, Real MI, Llach J, Montana X, et al. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology. 2002;225(1):27–34. https://doi.org/10.1148/radiol.2243011517.

    Article  PubMed  Google Scholar 

  76. Ben-David MA, Griffith KA, Abu-Isa E, Lawrence TS, Knol J, Zalupski M, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):772–9. https://doi.org/10.1016/j.ijrobp.2006.05.061.

    Article  PubMed  Google Scholar 

  77. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2016;27(suppl 5):v28–37. https://doi.org/10.1093/annonc/mdw324.

    Article  CAS  Google Scholar 

  78. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004;101(3):578–86. https://doi.org/10.1002/cncr.20368.

    Article  CAS  PubMed  Google Scholar 

  79. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008;98(2):309–15. https://doi.org/10.1038/sj.bjc.6604178.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Annals of Ooncology: Official Journal of the European Society for Medical Oncology. 2003;14(7):1115–20.

    Article  CAS  Google Scholar 

  81. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-Gastroenterology. 2001;48(39):783–9.

    CAS  PubMed  Google Scholar 

  82. Mezger J, Sauerbruch T, Ko Y, Wolter H, Funk C, Glasmacher A. Phase II study with gemcitabine in gallbladder and biliary tract carcinomas. Oncol Res Treat. 1998;21(3):232–4.

    Article  Google Scholar 

  83. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001;12(2):183–6.

    Article  CAS  PubMed  Google Scholar 

  84. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(10):2332–8. https://doi.org/10.1200/jco.2005.51.008.

    Article  CAS  Google Scholar 

  85. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer. 2005;104(12):2753–8. https://doi.org/10.1002/cncr.21591.

    Article  CAS  PubMed  Google Scholar 

  86. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer. 2007;110(6):1307–12. https://doi.org/10.1002/cncr.22902.

    Article  CAS  PubMed  Google Scholar 

  87. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008;53(2):564–70. https://doi.org/10.1007/s10620-007-9885-2.

    Article  CAS  PubMed  Google Scholar 

  88. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16(2):279–81. https://doi.org/10.1093/annonc/mdi046.

    Article  CAS  PubMed  Google Scholar 

  89. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer. 2006;106(6):1339–46. https://doi.org/10.1002/cncr.21741.

    Article  CAS  PubMed  Google Scholar 

  90. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15(2):168–81. https://doi.org/10.1634/theoncologist.2009-0302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721.

    Article  CAS  PubMed  Google Scholar 

  92. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15(9):1339–43. https://doi.org/10.1093/annonc/mdh351.

    Article  CAS  PubMed  Google Scholar 

  93. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer. 2006;95(7):848–52. https://doi.org/10.1038/sj.bjc.6603334.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Gebbia N, Verderame F, Di Leo R, Santangelo D, Cicero G, Valerio MR, et al. A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers. J Clin Oncol. 2005;23(16_suppl):4132. https://doi.org/10.1200/jco.2005.23.16_suppl.4132.

    Article  Google Scholar 

  95. Sharma A, Shukla NK, Chaudhary SP, Sahoo R, Mohanti BK, Deo SVS, et al. Final results of a phase III randomized controlled trial comparing modified gemcitabine + oxaliplatin (mGEMOX) to gemcitabine+ cisplatin in management of unresectable gall bladder cancer (GBC). J Clin Oncol. 2016;34(15_suppl):4077. https://doi.org/10.1200/JCO.2016.34.15_suppl.4077.

    Article  Google Scholar 

  96. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a north central Cancer treatment group phase II trial. Cancer. 2005;103(1):111–8. https://doi.org/10.1002/cncr.20753.

    Article  CAS  PubMed  Google Scholar 

  97. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol: Official Journal of the American Society of Clinical Oncology. 2001;19(20):4089–91. https://doi.org/10.1200/jco.2001.19.20.4089.

    Article  CAS  Google Scholar 

  98. Julka PK, Puri T, Rath GK. A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int: HBPD INT. 2006;5(1):110–4.

    CAS  PubMed  Google Scholar 

  99. Malka D, Trarbach T, Fartoux L, Mendiboure J, de la Fouchardière C, Viret F, et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol. 2009;27(15S):4520. https://doi.org/10.1200/jco.2009.27.15s.4520.

    Article  Google Scholar 

  100. El-Khoueiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE, Blanke CD. SWOG 0514: A phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol. 2007;25(18_suppl):4639. https://doi.org/10.1200/jco.2007.25.18_suppl.4639.

    Article  Google Scholar 

  101. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54. https://doi.org/10.1016/s1470-2045(09)70333-x.

    Article  CAS  PubMed  Google Scholar 

  102. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(21):3491–7. https://doi.org/10.1200/jco.2010.28.4075.

    Article  CAS  Google Scholar 

  103. Brechon M, Dior M, Dreanic J, Brieau B, Guillaumot MA, Brezault C, et al. Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. Investig New Drugs. 2017; https://doi.org/10.1007/s10637-017-0492-6.

  104. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706. https://doi.org/10.1146/annurev-immunol-020711-075008.

    Article  CAS  PubMed  Google Scholar 

  105. Goldstein D, Lemech C, Valle J. New molecular and immunotherapeutic approaches in biliary cancer. ESMO Open. 2017;2(Suppl 1) https://doi.org/10.1136/esmoopen-2016-000152.

  106. Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: current status and emerging strategies. World J Gastrointest Oncol. 2015;7(11):338–46. https://doi.org/10.4251/wjgo.v7.i11.338.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Bang YJ, Doi T, Braud FD, Piha-Paul S, Hollebecque A, Razak ARA, et al. 525 safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028. Eur J Cancer. 51:S112. https://doi.org/10.1016/S0959-8049(16)30326-4.

  108. Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. Journal of Surgical Oncology 2007;96(1):8–13. https://doi.org/10.1002/jso.20831.

  109. Cho SY, Kim SH, Park SJ, Han SS, Kim YK, Lee KW, et al. Adjuvant chemoradiation therapy in gallbladder cancer. Journal of Surgical Oncology 102(1):87–93. https://doi.org/10.1002/jso.21544.

  110. González ME, Giannini OH, González P, Saldaña B. Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer. Clinical and Translational Oncology 2011;13(7):480–4. https://doi.org/10.1007/s12094-011-0685-y.

  111. Gu B, Qian L, Yu H, Hu J, Wang Q, Shan J, et al. Concurrent Chemoradiotherapy in Curatively Resected Gallbladder Carcinoma: A Propensity Score–Matched Analysis. International Journal of Radiation Oncology*Biology*Physics 2018;100(1):138–45. https://doi.org/10.1016/j.ijrobp.2017.09.029.

  112. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?. Cancer 2002;95(8):1685–95. https://doi.org/10.1002/cncr.10831.

  113. Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. Journal of Clinical Oncology 2019;37(8):658–67. https://doi.org/10.1200/JCO.18.00050.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

    Amit Mahipal & Gaurav Goyal

  2. Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC, USA

    Anuhya Kommalapati & Sri Harsha Tella

  3. Department of Transplantation, and Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA

    Tushar C. Patel

  4. Department of Radiology, Mayo Clinic, Rochester, MN, USA

    Candice A. Bookwalter

  5. Department of Surgery, Mayo Clinic, Rochester, MN, USA

    Sean P. Cleary

  6. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA

    Christopher L. Hallemeier

  7. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Rondell P. Graham

Authors
  1. Amit Mahipal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anuhya Kommalapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sri Harsha Tella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gaurav Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tushar C. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Candice A. Bookwalter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sean P. Cleary
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christopher L. Hallemeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rondell P. Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amit Mahipal .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

    Lewis R. Roberts

  2. Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Ju Dong Yang

  3. Department of Radiology, Mayo Clinic, Rochester, MN, USA

    Sudhakar K. Venkatesh

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mahipal, A. et al. (2020). Gallbladder Cancer. In: Roberts, L., Yang, J., Venkatesh, S. (eds) Evaluation and Management of Liver Masses. Springer, Cham. https://doi.org/10.1007/978-3-030-46699-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-46699-2_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-46698-5

  • Online ISBN: 978-3-030-46699-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation